60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
0.8759
-0.0141 (-1.58%)
At close: Oct 22, 2026, 4:00 PM EDT
0.8500
-0.0259 (-2.96%)
After-hours: Oct 22, 2026, 6:20 PM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $207.90K in the quarter ending June 30, 2026, a decrease of -32.47%. This brings the company's total for the last twelve months to $1.21M, up 23.41% year-over-year. In the year 2025, 60 Degrees Pharmaceuticals had annual revenue of $1.41M with 106.81% growth. That makes 60 Degrees Pharmaceuticals the 43,274th largest company in the world by revenue and 6,001st in the United States.
Revenue (ttm)
$1.21M
Revenue Growth
+23.41%
P/S Ratio
2.54
Revenue / Employee
$404,977
Employees
3
Market Cap
3.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.41M | 727.75K | 106.81% |
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| VivoSim Labs | 112.00K |
| Addex Therapeutics | 102.81K |
| Jupiter Neurosciences | 64.69K |
| Ernexa Therapeutics | 1.00K |
SXTP News
- 16 days ago - 60 Degrees Pharmaceuticals Transcript: Study update - Transcripts
- 16 days ago - 60 Degrees Pharmaceuticals Press release: Study update - Filings
- 16 days ago - 60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study - TheFly
- 16 days ago - 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA - GlobeNewsWire
- 21 days ago - 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar - GlobeNewsWire
- 5 weeks ago - 60 Degrees Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results - GlobeNewsWire